Funding
Funding not disclosed
Founders
Product
Problem
Many drugs administered via inhalation have limited efficacy because only a small fraction of the medication reaches the deep lung tissue where it is needed. Existing inhalation devices and formulations often result in inconsistent drug delivery and suboptimal absorption, leading to reduced therapeutic effects. Oral medications for conditions like erectile dysfunction and pain management can take a long time to take effect and cause systemic side effects.
Solution
Asia Scientific Global (ASG) is developing novel inhalation drugs using a proprietary dry powder formulation and device technology platform (aPPC) to improve targeted drug delivery through the respiratory tract. ASG's Aero-Particles Process Control Technology precisely controls particle size and flowability, ensuring that a higher percentage of the inhaled drug reaches the deep lung. By combining optimized formulations with customized inhaler devices, ASG aims to create new dosage forms and new drugs with enhanced therapeutic effects, faster absorption, and reduced systemic side effects. The company is focused on developing inhaled formulations for antibiotics, erectile dysfunction, respiratory therapies, and central nervous system disorders.
Target Audience
ASG's target audience includes patients with respiratory diseases, infectious diseases, erectile dysfunction, and chronic pain, as well as healthcare providers seeking more effective and convenient drug delivery methods.
Features
- Aero-Particles Process Control Technology (aPPC) for precise control over drug particle size and flow properties
- Novel dry powder formulations designed for optimal dispersion and deep lung deposition
- Custom-designed dry powder inhalers tailored to specific drug formulations and patient needs
- Reformulation of existing drugs (505(b)(2) pathway) to improve efficacy and reduce side effects
- Development of inhaled antibiotics for improved treatment of respiratory infections like tuberculosis
- Inhaled PDE5 inhibitors for erectile dysfunction with faster onset and reduced systemic effects
- Inhaled mucolytics for targeted treatment of chronic respiratory diseases
- Inhaled analgesics for rapid pain relief with reduced systemic exposure
- AI-powered machine learning platform for analysis of clinical trial data and drug utilization patterns
- Electronic sensor technology integrated into inhalers to monitor usage and adherence